CD274 and non-small cell lung carcinoma: Combination of atezolizumab (anti-PD-L1) with tiragolumab (anti-TIGIT) in the CITYSCAPE trial provided substantially improved response rate and progression-free survival compared to atezolizumab alone in previously untreated PD-L1-positive NSCLC patients [256].